CENTERVILLE, Mass., May 15, 2012 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT)(the "Company") is pleased to announce that Cardis Furniture (www.cardis.com) has chosen the Company's Viratech UV-400 as the air purifier to be combined with a premium Serta Mattress as the Ultimate Sleep System for promoting a sound sleep. Cardis was chosen as the first furniture chain in the country to launch this Serta sleep system, which is expected to be rolled out nationally over the next 12 months.
"We're thrilled to be associated with Cardis Furniture for the initial launch of the Serta Sleep System," said Jack Lennon, President of UV Flu Technologies. "Cardis is renown in the industry for their attention to customer service, and to issues that will promote a healthier environment for their customers, while they spend time indoors. Recent clinical studies have shown direct links between Indoor Air Pollution and sleep-related problems, as well as allergies, asthma, diabetes, and even stroke. Combining one of the best mattresses available, with a best-in-class Viratech Air Purifier, we believe will give customers the soundest sleep they have ever experienced."
"The combination of these two products we think will take the industry by storm," said Nick, Ron, and Pete Cardi, owners of Cardi's Furniture, in a joint statement. "Combining a specially made, Serta mattress, with one of the only residential FDA-cleared air purifiers, which kills airborne bacteria, odors, volatile organic compounds (VOC's), along with a host of other airborne contaminants, will keep our customers breathing better, sleeping sounder, and waking up happy and well-rested," echoed the brothers.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.
In addition, the Company's RxAir subsidiary in Dallas, TX, makes one of the world's finest lines of hospital-grade HEPA filtration products. The RX-3000, the Company's main product, is currently in almost 450 hospitals internationally, is FDA-cleared as a Class II Medical Device, and has been shown to capture 99.99% of all airborne contaminants. The Company's product lines are in Hospitals, government buildings, casinos and restaurants around the world.
For more information, visit: www.uvflutech.com. Or www.rxair.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
SOURCE UV Flu Technologies, Inc.